2017
Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial)
Alenezi F, Brummett BH, Boyle SH, Samad Z, Babyak MA, Alzaeim N, Wilson J, Romano MMD, Sun JL, Ersboll M, O'Connor CM, Velazquez EJ, Jiang W. Usefulness of Myocardial Annular Velocity Change During Mental Stress to Predict Cardiovascular Outcome in Patients With Coronary Artery Disease (From the Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram Treatment Trial). The American Journal Of Cardiology 2017, 120: 1495-1500. PMID: 28917493, DOI: 10.1016/j.amjcard.2017.07.039.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseStable coronary artery diseaseAdverse cardiovascular outcomesCardiovascular outcomesArtery diseaseNew York Heart Association functional class IMental stress-induced myocardial ischemiaStress-induced myocardial ischemiaNonfatal cardiovascular eventsFunctional class IMental stress testingCox regression modelMS-induced changesCardiovascular eventsCause mortalityUnplanned hospitalizationPrognostic factorsMean ageMyocardial ischemiaSystolic velocityAnnular velocityPatientsMental stressClass IMACE
2016
Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link?
Peña M, Dunning A, Schulte PJ, Durheim MT, Kussin P, Checkley W, Velazquez EJ. Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link? Respiratory Medicine 2016, 121: 4-12. PMID: 27888991, DOI: 10.1016/j.rmed.2016.10.009.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionAdverse cardiovascular eventsPulmonary functionCause mortalityCardiovascular eventsCardiac hospitalizationCardiac functionDecreased LVEFNormal left ventricular ejection fractionSingle tertiary care medical centerTertiary care medical centerCox proportional hazards modelLeft heart remodelingRight heart dysfunctionAdverse cardiovascular outcomesRight ventricular functionTertiary care centerVentricular ejection fractionVentricular internal dimensionLeft heart structuresLeft heart sizeProportional hazards modelMultivariable linear regressionDecreased FVCCardiovascular outcomesCardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy
Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. Journal Of Clinical Hypertension 2016, 18: 299-307. PMID: 27060568, PMCID: PMC8032014, DOI: 10.1111/jch.12816.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureBlood Pressure DeterminationDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesHumansHypertensionIncidenceMaleMyocardial InfarctionProspective StudiesRisk AssessmentRisk FactorsStrokeSurvival RateSystoleTreatment OutcomeUnited StatesConceptsSystolic blood pressureNondiabetic cohortCardiovascular outcomesPrimary endpointBlood pressurePrimary endpoint event rateTreatment systolic blood pressureEvent ratesAvoiding Cardiovascular EventsBlood pressure targetsDifferent SBP targetsFurther SBP reductionSystolic Hypertension (ACCOMPLISH) trialAdverse renal eventsComposite primary endpointTotal stroke ratesCV protectionNondiabetic patientsRenal considerationsRenal eventsSBP categoriesSBP reductionCardiovascular eventsHypertension trialsPressure targets
2014
Clinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease
Holmqvist F, Thomas KL, Broderick S, Ersbøll M, Singh D, Chiswell K, Shaw LK, Hegland DD, Velazquez EJ, Daubert JP. Clinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease. EP Europace 2014, 17: 978-985. PMID: 25164430, DOI: 10.1093/europace/euu211.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseHeart diseaseDuke University Medical CenterMajor cardiovascular outcomesMajor cardiovascular eventsNative coronary arteriesUniversity Medical CenterPR interval durationCV eventsCardiovascular eventsCardiovascular outcomesCause mortalityCoronary angiographyDuke DatabankClinical outcomesAtrial fibrillationPoor outcomeCoronary arterySignificant stenosisSinus rhythmCardiovascular diseaseMedical CenterHigh riskPatientsRelevant covariates
2013
Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. The American Journal Of Medicine 2013, 126: 501-508. PMID: 23541376, DOI: 10.1016/j.amjmed.2013.01.007.Peer-Reviewed Original ResearchConceptsSystolic blood pressureHigh-risk hypertensive patientsPrimary end pointBlood pressure levelsSystolic bloodBlood pressureCardiovascular deathCardiovascular eventsCardiovascular outcomesCoronary eventsEnd pointHypertensive patientsMyocardial infarctionSystolic blood pressure levelsAvoiding Cardiovascular EventsSystolic Hypertension (ACCOMPLISH) trialTotal myocardial infarctionBlood pressure groupMajor cardiovascular eventsMean patient ageNonfatal myocardial infarctionCardiovascular event ratesRenal end pointsLower blood pressureTreatment of hypertension
2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 2012, 381: 537-545. PMID: 23219284, DOI: 10.1016/s0140-6736(12)61343-9.Peer-Reviewed Original ResearchConceptsCardiovascular event ratesBody mass indexNormal weightPrimary endpointObese patientsEvent ratesCardiovascular outcomesCardiovascular protectionHypertension treatmentObese individualsHigher cardiovascular event ratesHigh-risk hypertensive patientsNon-fatal myocardial infarctionAmlodipine-based therapyAvoiding Cardiovascular EventsPatient’s cardiovascular outcomeSuperior cardiovascular protectionSystolic Hypertension (ACCOMPLISH) trialPrimary event rateSingle-pill combinationPrevious clinical trialsNormal weight categoryCardiovascular deathCardiovascular eventsHypertension trials
2011
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Östergren J, Ibsen H, Weber M, INVESTIGATORS F. Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Pressure 2011, 21: 82-87. PMID: 21830844, DOI: 10.3109/08037051.2011.598699.Peer-Reviewed Original ResearchConceptsSystolic blood pressureBetter SBP controlPrevious antihypertensive medicationsSBP controlAntihypertensive medicationsBaseline predictorsTreatment groupsHigher baseline systolic blood pressureCalcium channel blocker useUncontrolled systolic blood pressureHigher systolic blood pressureBaseline systolic blood pressureMain baseline predictorsUse of thiazidesSystolic BP levelsHigher diastolic BPMultivariable regression modelsLogistic regression modelsACCOMPLISH trialAmlodipine armRandomization armBlocker useCardiovascular outcomesInsulin useSystolic hypertension
2010
Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both
Shin SH, Hung CL, Uno H, Hassanein AH, Verma A, Bourgoun M, Køber L, Ghali JK, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD. Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both. Circulation 2010, 121: 1096-1103. PMID: 20176989, DOI: 10.1161/circulationaha.109.863795.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalog-Digital ConversionAngiotensin II Type 1 Receptor BlockersDeathDisease ProgressionFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMotionMyocardial ContractionMyocardial InfarctionPrognosisProportional Hazards ModelsStress, MechanicalTetrazolesUltrasonographyValineValsartanVentricular Dysfunction, LeftVideo RecordingConceptsSD of timeLeft ventricular dysfunctionHeart failureMyocardial infarctionMechanical dyssynchronyVentricular dysfunctionIndependent predictorsPost-myocardial infarction prognosisPeak velocityAdverse cardiovascular outcomesMultivariate Cox modelRisk of deathLeft ventricular segmentsMeasures of dyssynchronyVelocity vector imagingCardiovascular outcomesEchocardiographic variablesVentricular synchronyVentricular dyssynchronyClinical outcomesEchocardiography studyRisk factorsContractile patternsVentricular segmentsCox model
2008
High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD. High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2008, 155: 706-711. PMID: 18371480, DOI: 10.1016/j.ahj.2007.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDiabetes ComplicationsFemaleHumansHypertensionKaplan-Meier EstimateMaleMiddle AgedMortalityMultivariate AnalysisMyocardial InfarctionProportional Hazards ModelsRisk FactorsSex FactorsSmokingSurvivorsTetrazolesValineValsartanConceptsAcute myocardial infarctionAcute Myocardial Infarction trialMyocardial Infarction trialRisk factorsMyocardial infarctionHigh-risk myocardial infarctionCardiovascular event ratesInfluence of hypertensionMultivariate Cox regressionPrognostic risk factorsHistory of MICardiovascular outcomesCurrent smokersLess diabetesYounger patientsCox regressionPost-AMIAdvanced ageRelative riskYoung survivorsAge groupsHypertensionEvent ratesPatientsOutcomes
2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function
Amigoni M, Meris A, Thune JJ, Mangalat D, Skali H, Bourgoun M, Warnica JW, Barvik S, Arnold JM, Velazquez EJ, Van de Werf F, Ghali J, McMurray JJ, Køber L, Pfeffer MA, Solomon SD. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. European Heart Journal 2007, 28: 326-333. PMID: 17251259, DOI: 10.1093/eurheartj/ehl464.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac VolumeDisease ProgressionEchocardiography, Doppler, ColorElectrocardiographyFemaleHeart FailureHumansMaleMiddle AgedMitral Valve InsufficiencyMyocardial InfarctionObserver VariationPrognosisProspective StudiesRandomized Controlled Trials as TopicRisk FactorsVentricular Dysfunction, LeftVentricular RemodelingConceptsProgression of MRBaseline mitral regurgitationHeart failureMitral regurgitationAcute myocardial infarctionMyocardial infarctionVentricular sizeMR severityHigh-risk myocardial infarctionModerate-severe mitral regurgitationBaseline MR severityWorse LV functionEnd-systolic volumeLarger LV volumesRegurgitant jet areaAtrial area ratioCV mortalityHF hospitalizationCardiovascular outcomesSystolic dysfunctionVentricular dysfunctionEjection fractionIndependent predictorsClinical outcomesLV function
2006
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience
Stephenson K, Skali H, McMurray JJ, Velazquez EJ, Aylward PG, Kober L, Van de Werf F, White HD, Pieper KS, Califf RM, Solomon SD, Pfeffer MA. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. Heart Rhythm 2006, 4: 308-313. PMID: 17341394, DOI: 10.1016/j.hrthm.2006.11.021.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBundle-Branch BlockCaptoprilElectrocardiographyFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsProportional Hazards ModelsResearch DesignRisk FactorsStroke VolumeSurvival AnalysisSurvivorsTetrazolesTime FactorsTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsNew left bundle branch blockLeft bundle branch blockLV systolic dysfunctionHigh-risk survivorsHeart failureMyocardial infarctionBundle branch blockSystolic dysfunctionCardiovascular outcomesIndependent predictorsBranch blockLeft ventricular systolic dysfunctionLong-term cardiovascular complicationsMajor adverse cardiovascular outcomesAcute Myocardial Infarction trialBaseline ECG dataMajor cardiovascular outcomesPost-MI survivorsComposite of deathMyocardial Infarction trialVentricular systolic dysfunctionAdverse cardiovascular outcomesHigh-risk patientsLV ejection fractionLong-term outcomesExtent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
Janardhanan R, Kenchaiah S, Velazquez EJ, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD, Investigators F. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. American Heart Journal 2006, 152: 183-189. PMID: 16824854, DOI: 10.1016/j.ahj.2005.11.013.Peer-Reviewed Original ResearchConceptsExtent of CADCoronary artery diseaseAcute myocardial infarctionHeart failureCV outcomesMyocardial infarctionCause mortalityArtery diseaseSeverity of CADVentricular systolic dysfunctionAdverse CV outcomesHigh-risk patientsIndependent risk factorSingle-vessel diseasePredictors of outcomeProportional hazards modelCoronary angiography dataCaptopril monotherapyValsartan monotherapyCardiovascular outcomesSystolic dysfunctionVentricular dysfunctionHazard ratioEjection fractionPoor outcome
2004
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal Of Medicine 2004, 351: 1285-1295. PMID: 15385655, DOI: 10.1056/nejmoa041365.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCardiovascular DiseasesChronic DiseaseCreatinineDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansKidney DiseasesMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsRisk FactorsSurvival RateTetrazolesValineValsartanConceptsGlomerular filtration rateAcute myocardial infarctionMyocardial infarctionCardiovascular outcomesHeart failureRisk factorsAcute Myocardial Infarction trialFour-component ModificationNonfatal cardiovascular outcomesMyocardial Infarction trialUse of aspirinComposite cardiovascular eventsComposite end pointRenal Disease equationCongestive heart failureMild renal diseaseRisk of deathCoronary revascularization proceduresMajor risk factorSerum creatinine measurementsBody surface areaCardiovascular causesKillip classRenal eventsCardiovascular complicationsRationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial
Jamerson K, Bakris G, Wun C, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez E, Weber M. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. American Journal Of Hypertension 2004, 17: 793-801. PMID: 15363822, DOI: 10.1016/j.amjhyper.2004.05.004.Peer-Reviewed Original ResearchConceptsSystolic Hypertension (ACCOMPLISH) trialCardiovascular eventsBlood pressureHypertension trialsCombination therapyOptimal BP controlPrimary study endpointCalcium channel blockersClass of drugsBP controlCardiovascular outcomesHypertensive patientsPrimary endpointCardiovascular mortalityStudy endpointACE inhibitorsHypertension managementFirst patientClinical eventsAntihypertensive combinationsRisk factorsSuch therapyRecent guidelinesDrug classesVasculoprotective properties
2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau J, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM, Investigators F. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal Of Heart Failure 2003, 5: 537-544. PMID: 12921816, DOI: 10.1016/s1388-9842(03)00112-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin Receptor AntagonistsCaptoprilDouble-Blind MethodFemaleGlyceraldehyde-3-Phosphate DehydrogenasesHeart FailureHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPeptide FragmentsRandomized Controlled Trials as TopicTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsAcute Myocardial Infarction trialAngiotensin receptor blockadeMyocardial Infarction trialHeart failureMyocardial infarctionACEI trialsRenin-angiotensin system blockadePlacebo-controlled trialVentricular systolic dysfunctionActive-controlled trialEvidence-based careHigh-risk populationEvidence-based therapiesCardiovascular outcomesSystem blockadeSystolic dysfunctionBaseline characteristicsStandard treatmentRepresentative cohortPatientsMI trialsTrialsValsartanACEIsLVSD